{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nitrogen+%28placebo%29&page=7", "query": { "intervention": "Nitrogen (placebo)", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 266, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nitrogen+%28placebo%29&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Nitrogen+%28placebo%29&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T10:27:24.486Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02873819", "title": "Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Oral Cavity" ], "interventions": [ { "name": "GL-0817", "type": "DRUG" }, { "name": "Hiltonol", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gliknik Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2017-03-30", "completion_date": "2021-05-25", "has_results": false, "last_update_posted_date": "2022-03-08", "last_synced_at": "2026-10-10T10:27:24.486Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02873819" }, { "nct_id": "NCT01907100", "title": "Nintedanib (BIBF 1120) in Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 545, "start_date": "2013-09-19", "completion_date": "2018-08-31", "has_results": true, "last_update_posted_date": "2019-03-18", "last_synced_at": "2026-10-10T10:27:24.486Z", "location_count": 10, "location_summary": "Birmingham, Alabama • San Francisco, California • Littleton, Colorado + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Henderson", "state": "Nevada" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01907100" }, { "nct_id": "NCT01401517", "title": "Phase IIa: Safety, PK, & Tolerability of Sodium Nitrite in Patients With Peripheral Arterial Disease-SONIC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral Arterial Disease" ], "interventions": [ { "name": "sodium nitrite", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TheraVasc Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "35 Years to 85 Years" }, "enrollment_count": 55, "start_date": "2011-07", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2020-04-21", "last_synced_at": "2026-10-10T10:27:24.486Z", "location_count": 10, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Iowa City, Iowa + 6 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01401517" }, { "nct_id": "NCT04603378", "title": "A Clinical Study to Assess the Effect of Novel Glycans on Nitrogen Metabolism of the Gut in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "KB195", "type": "OTHER" }, { "name": "Polydextrose", "type": "OTHER" }, { "name": "Pullulan", "type": "OTHER" }, { "name": "Maltodextrin", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Kaleido Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 47, "start_date": "2017-09-18", "completion_date": "2017-11-28", "has_results": false, "last_update_posted_date": "2020-10-26", "last_synced_at": "2026-10-10T10:27:24.486Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04603378" }, { "nct_id": "NCT04634877", "title": "Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo for pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "External Beam Radiotherapy (EBRT)", "type": "RADIATION" }, { "name": "Cisplatin (as radiosensitizer)", "type": "DRUG" }, { "name": "Brachytherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 990, "start_date": "2021-01-10", "completion_date": "2026-11-20", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-10T10:27:24.486Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634877" }, { "nct_id": "NCT03189719", "title": "First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 749, "start_date": "2017-07-25", "completion_date": "2023-07-10", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-10-10T10:27:24.486Z", "location_count": 12, "location_summary": "West Los Angeles, California • Chicago, Illinois • Westwood, Kansas + 9 more", "locations": [ { "city": "West Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03189719" }, { "nct_id": "NCT00570349", "title": "Safety and Tolerability of Inhaled Nitric Oxide in Patients With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "Nitric Oxide for Inhalation", "type": "DRUG" }, { "name": "Nitrogen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mallinckrodt", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 18, "start_date": "2004-07", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2019-11-13", "last_synced_at": "2026-10-10T10:27:24.486Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00570349" }, { "nct_id": "NCT06686121", "title": "Improving Mobility After Revascularization in Peripheral Artery Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Peripheral Artery Disease", "Intermittent Claudication", "Peripheral Vascular Disease", "Mobility Limitation", "Revascularization" ], "interventions": [ { "name": "Home Based Exercise", "type": "BEHAVIORAL" }, { "name": "Nitrate Rich Beetroot Juice", "type": "DRUG" }, { "name": "Attention Control", "type": "BEHAVIORAL" }, { "name": "Placebo Beetroot Juice Without Nitrate", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 386, "start_date": "2025-08-04", "completion_date": "2032-08-01", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-10T10:27:24.486Z", "location_count": 8, "location_summary": "Tucson, Arizona • Downey, California • Tampa, Florida + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Downey", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06686121" }, { "nct_id": "NCT00000262", "title": "Effects of Combined Sevoflurane and Nitrous Oxide Inhalation - 14", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Opioid-Related Disorders", "Substance-Related Disorders" ], "interventions": [ { "name": "30% Nitrous oxide", "type": "DRUG" }, { "name": "0.4% Sevoflurane", "type": "DRUG" }, { "name": "0.2% sevoflurane", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20, "start_date": "1996-11", "completion_date": "1999-02", "has_results": false, "last_update_posted_date": "2015-05-27", "last_synced_at": "2026-10-10T10:27:24.486Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000262" }, { "nct_id": "NCT01064479", "title": "Combination Chemotherapy With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Squamous Cell Carcinoma of the Hypopharynx", "Metastatic Squamous Cell Carcinoma of the Larynx", "Metastatic Squamous Cell Carcinoma of the Oral Cavity", "Metastatic Squamous Cell Carcinoma of the Oropharynx", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7", "Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7", "Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7", "Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Erlotinib Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2010-02-05", "completion_date": "2020-11-03", "has_results": true, "last_update_posted_date": "2024-07-16", "last_synced_at": "2026-10-10T10:27:24.486Z", "location_count": 5, "location_summary": "Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Nassau Bay", "state": "Texas" }, { "city": "Sugar Land", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01064479" } ] }